The binding of thyroid hormone to the thyroid hormone receptor (TR) mediates important physiological effects. However, the transcriptional effects of TR mediated by the thyroid response element (TRE) cannot explain many actions of thyroid hormone. We postulate that TR can initiate rapid, non-TRE-mediated effects in the cardiovascular system through cross-coupling to the phosphatidyl- 
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hyroid hormone exerts many physiological effects. It increases tissue thermogenesis and metabolism, decreases systemic vascular resistance (SVR) and arterial blood pressure (BP), enhances renal sodium reabsorption and blood volume, and augments cardiac inotropy and chronotropy (1) . All of these effects lead to a dramatic increase in cardiac output, which is a prominent feature of hyperthyroidism. In contrast, elevated SVR is observed in thyroid hormone deficiency or hypothyroidism and is rapidly reversed with thyroid hormone replacement. However, the precise mechanism by which thyroid hormone regulates vascular tone and SVR is not known.
The actions of thyroid hormone occur through its binding to the thyroid hormone receptor (TR) (2) . TR is a nuclear hormone receptor, which heterodimerizes with retinoid X receptor, or in some cases, with itself. The dimers bind to the thyroid response elements (TREs) in the absence of ligand and act as transcriptional repressors. An active form of thyroid hormone, L-3,5,3Ј-triiodothyronine (T 3 ), binds to TR with much greater affinity than the more abundant L-3,5,3Ј5Ј-tetraiodothyronine (T 4 ). Binding of T 3 to TR derepresses TRE-dependent genes and induces the expression of target genes such as ␣-myosin heavy chain, sarcoplasmic reticulum Ca 2ϩ -ATPase, ␤ 1 -adrenergic receptors, guanine-nucleotide-regulatory proteins, Na ϩ ͞K ϩ -ATPase, and voltage-gated potassium channels (Kv1.5, Kv4.2, and Kv4.3) in heart (1) . Through TRE, T 3 can also downregulate the expression of ␤-myosin heavy chain, phospholamban, adenylyl cyclase types V and VI, Na ϩ ͞Ca 2ϩ exchanger, and the TR isoform TR␣ 1 (1) . In addition to these genomic or TRE-mediated effects of T 3 , non-nuclear or TRE-independent actions of T 3 have recently been described. For example, T 3 rapidly modulates membrane potential, cellular depolarization, and contractile activity by regulating ion flux across plasma membrane ion channels (3) (4) (5) . Furthermore, in mice possessing a mutant form of TR␤ that cannot bind to TRE, thyroid hormone, which is known to regulate outer hair cell development in the ear via TR␤, is still able to induce the development of these hair cells (6) . These findings suggest that TR may have actions beyond TRE-mediated gene transcription and that non-TREdependent effects of TR may contribute to important physiological effects of thyroid hormone.
The phosphatidylinositol 3-kinase (PI3-kinase)͞protein kinase Akt pathway is an important regulator of cellular growth, metabolism, and survival (7, 8) . For example, Akt is known to block apoptosis via the serine-threonine phosphorylation of multiple targets, including phosphorylation and inhibition of glycogen synthase kinase (GSK)-3, inactivation of the BCL-2 family member BAD, and inhibition of cell death pathway enzyme caspase-9 (8-10). Another important downstream target of Akt is endothelial nitric oxide synthase (eNOS), which is phosphorylated and activated by Akt (11, 12) . Mice with targeted deletion of eNOS have enlarged cerebral and myocardial infarct size after transient ischemia (13, 14) . Therefore, it is likely that the regulation of eNOS activity by Akt in endothelial cells is an important mediator of vascular function.
Recently, members of the steroid hormone receptor superfamily, such as the estrogen, vitamin D, and glucocorticoid receptors, have been shown to cross-couple to the PI3-kinase͞ Akt pathway (15) (16) (17) (18) . In vascular endothelial cells, the activation of the PI3-kinase͞Akt pathway by steroid hormones leads to eNOS activation and cardiovascular protection (16, 18) . Indeed, thyroid hormone has recently been shown to modulate the interaction of TR␤ or a mutant form of TR␤ with PI3-kinase (19) (20) (21) . Whether this accounts for some of the rapid, non-TRE effects of TR in the cardiovascular system remains to be determined.
The purpose of this study, therefore, is to show that PI3-kinase͞Akt and eNOS can mediate some of the rapid, nonnuclear, cardiovascular effects of TR. The ability of TR to activate PI3-kinase͞Akt and eNOS may be physiologically important and perhaps therapeutically beneficial because steroid hormone therapy may exert side effects, which may limit their overall clinical use.
Results

TR Expression in Endothelial
Cells. There are two major isoforms of TR, TR␣ 1 and TR␤ 1 . TR␣ 1 is expressed in heart, brain, skeletal muscle, and adipose tissue, whereas TR␤ 1 is expressed at higher levels in liver and kidney (22, 23) . Because vascular tone is, in part, regulated by endothelium-derived NO, we examined the expression of TR isoforms in endothelial cells. By Northern blot analysis, TR␣ 1 and TR␣ 2 mRNA were detected in endothelial cells from bovine aorta and human umbilical vein (Fig. 1A) . In contrast, little, if any, TR␤ 1 mRNA was detected in endothelial cells. The robust expression of TR␤ 1 mRNA in NIH 3T3 fibroblasts, mouse embryonic fibroblasts (MEFs), and HeLa cells served as positive controls. These findings indicate that TR␣ 1 is the predominant TR isoform in vascular endothelial cells. Similar findings were observed by Western blot analysis where TR␣ 1 protein, and to a much lesser extent, TR␤ 1 protein, is detected in vascular endothelial cells (Fig. 1B) .
Phosphorylation and Activation of Akt by T3. To determine whether T 3 can activate Akt in endothelial cells, we serum-starved endothelial cells for Ͼ8 h before T 3 stimulation. Treatment with T 3 , at concentrations as low as 1 nM, increased Ser-473 phosphorylation of Akt within 20 min (Fig. 2 A and B) . The phosphorylation of Akt by T 3 was blocked by pretreatment with the PI3-kinase inhibitors, LY294002 and wortmannin (Fig. 6A , which is published as supporting information on the PNAS web site), but not by the transcriptional inhibitor, actinomycin D (Fig.  2C) , suggesting a nontranscriptional effect involving the PI3-kinase pathway. Interestingly, LY294002, but not wortmannin, decreased Akt phosphorylation below basal levels (Fig. 6 ). The increase in Akt phosphorylation by T 3 corresponded to an increase in Akt kinase activity as determined by the Akt downstream phosphorylation target, GSK-3␤. T 3 -induced GSK-3␤ phosphorylation was blocked by LY294002 (Fig. 2D ). Because higher levels (i.e., nM) of T 3 were required to activate Akt (compared with TRE-dependent responses, i.e., pM), we investigated whether TR mediated the effects of T 3 on Akt kinase activity in brain tissues derived from TR␣ 1 Ϫ/Ϫ ␤ Ϫ/Ϫ mice, which lack all known T 3 binding receptors. Compared with WT mice, T 3 did not stimulate Akt kinase activity in brain tissues from TR␣ 1 Ϫ/Ϫ ␤ Ϫ/Ϫ mice (Fig. 2E) . These findings indicate that T 3 rapidly activates the PI3-kinase͞Akt pathway through TR.
Interaction of TR␣1 with PI3-Kinase. To determine the mechanism of PI3-kinase͞Akt activation by TR, we investigated whether TR can interact with the regulatory subunit of PI3-kinase, p85␣, by using GST-p85␣ pull-down assays with in vitro-translated, radiolabeled [
35 S]TR␣ 1 and [ 35 S]TR␤ 1 . In a ligand-dependent manner, treatment with T 3 increased the association of TR␣ 1 , but not TR␤ 1 , with p85␣ ( Fig. 3A) . To determine whether endogenous p85␣ can interact with TR␣ 1 in intact endothelial cells, we performed coimmunoprecipitation studies using p85␣ and TR␣ 1 antibodies. Lysates from endothelial cells treated with T 3 were immunoprecipitated with p85␣ antibody followed by immunoblotting for TR␣ 1 or TR␤ 1 . Using this coimmmunoprecipitation assay, we found that T 3 increased the association of TR␣ 1 , but not TR␤ 1 (data not shown), with p85␣ ( Fig. 3B) . Similarly, lysates treated with T 3 , which were then coimmunnoprecipitated with a TR antibody (sc-739), showed greater amounts of ligand- dependent p85␣ (data not shown). These findings indicate that TR␣ 1 and p85␣ can associate in a ligand-dependent manner.
To determine whether the Src homology 2 (SH2) domains of p85␣ could be important for the association of p85␣ with TR␣ 1 , we used deletional N-terminal (N-SH2, amino acids 332-428) and C-terminal (C-SH2, amino acids 624-718) SH2 constructs of p85␣ in a GST pull-down assay with radiolabeled TR␣ 1 and TR␤ 1 . Both SH2 domains of p85␣ were important for liganddependent interaction of p85␣ with TR␣ 1 (Fig. 3C) . The TR antagonist, NH-3 (24), blocked the ligand-dependent interaction of TR␣ 1 with p85␣ (Fig. 3D ).
Phosphorylation and Activation of eNOS by T3. Because eNOS is an important downstream phosphorylation target of Akt in endothelial cells, we investigated whether T 3 can lead to eNOS phosphorylation and activation. Treatment of endothelial cells with T 3 , at a concentration as low as 0.1 nM, increased eNOS phosphorylation within 10-20 min (Fig. 4A) . The phosphorylation of eNOS was correlated with an increase in eNOS activity as measured by [ 3 H]L-arginine to [ 3 H]L-citrulline conversion and nitrite accumulation. In a time-dependent manner, T 3 (10 nM) increased eNOS activity with maximal activity occurring 30-60 min after stimulation (Fig. 4B) . The time course and dose dependency of eNOS activation are slightly earlier and lower, respectively, compared with Akt activation. For example, although a minimum of 1 nM of T 3 was required to observe an increase in Akt activation, increase eNOS activation was observed at T 3 concentrations as low as 0.1 nM (Fig. 4C ). This result may be caused by a greater sensitivity of and differences in the assays used to detect eNOS versus Akt activation (i.e., enzymatic assay versus antibody detection). Nevertheless, the time and dose dependency of Akt and eNOS activation were within 10-20 min and 0.1-1 nM of each other. The activation of both Akt and eNOS by T 3 was blocked by LY294002 and wortmannin, indicating that PI3-kinase mediates their activation by T 3 (Fig. 4D) .
Effects of T3 on BP. To determine the physiological relevance of this pathway in the cardiovascular system, we investigated the effects of T 3 on BP and cerebral blood flow (CBF) in mice.
Treatment of euthyroid WT mice with T 3 (500 ng, i.v. bolus) rapidly decreased mean BP within 5 min from 84.2 to 79.9 mmHg at 30 min (P Ͻ 0.01) (Fig. 5A) . The changes in mean BP were more substantial when propylthiouracil-treated hypothyroid WT mice were used (88.0 to 78.9 mmHg at 30 min after T 3 administration, P Ͻ 0.05) (Fig. 5B) . The acute decreases in mean BP with T 3 administration were greatly attenuated or abolished in euthyroid or hypothyroid eNOS Ϫ/Ϫ mice. These findings indicate that eNOS mediates most, if not all, of the rapid effects of T 3 on vascular tone and BP.
Effects of T3 on CBF and Infarct Size. To determine the hemodynamic consequences of T 3 on vascular tone, we measured absolute CBF by an indicator fractionation technique using radiolabeled [ 14 C]iodoamphetamine (25) (26) (27) . Despite acute decreases in mean BP, T 3 rapidly increased absolute CBF in WT mice (134 Ϯ 13 to 190 Ϯ 27 ml͞100 g per min, n ϭ 9 and 8, P Ͻ 0.05) (see Supporting Text, which is published as supporting information on the PNAS web site). In contrast, in eNOS Ϫ/Ϫ mice, there was a small, but nonsignificant, increase in absolute CBF with T 3 (135 Ϯ 12 to 162 Ϯ 14 ml͞100 g per min, n ϭ 4 and 5, P Ͼ 0.05). These findings suggest that eNOS is the primary mediator of a T 3 -induced increase in CBF, although another mechanism could not be completely excluded.
To determine whether the increase in CBF by T 3 corresponds to neuroprotection after focal ischemia, we subjected mice to intrafilament transient middle cerebral artery (MCA) occlusion (MCAO) (i.e., 2-h occlusion followed by 22-h reperfusion) as described (27, 28) . Cerebral infarct volumes were determined by summing up the infarcted areas as determined by 2,3,5-triphenyltetrazolium chloride staining in 2-mm-thick coronal sections of the brain. Administration of T 3 (30 min before occlusion) decreased cerebral infarct volume by 25% compared with vehicle-treated WT mice (85 Ϯ 4 mm 3 vs. 114 Ϯ 7 mm 3 , n ϭ 12 and 13, P Ͻ 0.05) (Fig. 5C and Fig. 7 , which is published as supporting information on the PNAS web site).
To determine whether reductions in cerebral infarct size correlated with improvement in neurological motor function, we assessed the neurological deficit score (NDS) in each mouse after MCAO. NDS was scored by two observers blinded to treatment protocol as follows: 0, no motor deficits (normal); 1, flexion of the contralateral torso and forelimb on lifting the animal by the tail (mild); 2, circling to the contralateral side but normal posture at rest (moderate); 3, leaning to the contralateral side at rest (severe); and 4, no spontaneous movement (critical).
The decrease in cerebral infarct volume by T 3 correlated with qualitative improvement in NDS (P Ͻ 0.05 by Mann-Whitney analysis of noncontinuous variables) (Fig. 5E) .
Treatment with T 3 , however, had little or no effect on cerebral infarct volume and NDS in eNOS Ϫ/Ϫ mice (P Ͼ 0.05 for both compared with vehicle-treated mice) (Fig. 5 D and F) , suggesting that the neurological benefits were caused primarily by eNOS. Furthermore, the neuroprotective effects of T 3 were not observed in WT mice pretreated with the PI3-kinase inhibitor, LY294002 (32.1 Ϯ 4.6% vs. 33.5 Ϯ 4.4% of infracted hemisphere, P Ͼ 0.05 compared with vehicle-treated mice) or with the TR antagonist, NH-3 (33.5 Ϯ 4.4% vs. 32.1 Ϯ 4.6% of infracted hemisphere, P Ͼ 0.05 compared with vehicle-treated mice). Indeed, administration of T 3 had no beneficial effects on cerebral infarct volume in TR␣ 1 Ϫ/Ϫ ␤ Ϫ/Ϫ mice (31.3 Ϯ 2.4% vs. 28.6 Ϯ 4.1% of infracted hemisphere, P Ͼ 0.05 compared with vehicletreated mice) (Fig. 5D ). These findings indicate the critical roles of TR, PI3-kinase͞Akt, and eNOS in mediating the acute neurovascular protective effects of T 3 .
Discussion
We have shown that thyroid hormone can nontranscriptionally activate the PI3-kinase͞Akt pathway. In a ligand-dependent manner, TR␣ 1 was shown to interact with PI3-kinase in intact endothelial cells by coimmunoprecipitation assay and in vitro by GST pull-down assay. The rapid activation of the PI3-kinase͞Akt pathway by T 3 led to an increase in eNOS activity, decrease in mean BP, augmentation of CBF, and reduction in cerebral infarct size. These results indicate that some of the hemodynamic effects of thyroid hormone are attributable to eNOS activation and suggest that the activation of Akt and eNOS by T 3 may be therapeutically beneficial in cardiovascular disease. Indeed, the activation of PI3-kinase͞Akt by TR is similar to other nuclear hormone receptors such as estrogen receptor and glucocorticoid receptor, which also activate the PI3-kinase͞Akt pathway and mediate cardiovascular protection (15, 16, 18) . However, administration of steroid hormones is often associated with significant untoward side effects such as increased risks of breast and uterine cancers and the development of hypertension and osteoporosis. These side effects of steroid hormones have precluded their use in cardiovascular diseases. Thus, the acute administration of thyroid hormone, compared with steroid hormones, may perhaps be a safer alternative for cardiovascular protection.
The obligatory role of TR in T 3 -induced eNOS activation and stroke protection is demonstrated by studies showing lack of stroke protection in the presence of TR antagonist, NH-3, and in TR␣ 1 Ϫ/Ϫ ␤ Ϫ/Ϫ or eNOS Ϫ/Ϫ mice. Although two different genes, THRA and THRB, encode the TR isoforms, TR␣ and TR␤, respectively (2), we have shown that the predominant TR isoform in vascular endothelial cells is TR␣ 1 . TR␣ 1 is a functional receptor for T 3 and is highly expressed in heart, brain, skeletal muscle, and brown fat (22) . In contrast to TR␣ 1 , TR␣ 2 does not bind thyroid hormone and act as a weak antagonist in vitro. TR␤ 1 is highly expressed in heart, brain, liver, and kidney (29), but we found that its expression is barely detectable in vascular endothelial cells. The alternatively spliced THRB gene encoding TR␤ 2 is almost exclusively expressed in the anterior pituitary and hypothalamus. Thus, in vascular endothelial cells, TR␣ 1 is the most likely TR isoform that mediates PI3-kinase͞ Akt͞eNOS activation. Indeed, TR␣ 1 , but not TR␤ 1 , interacts with PI3-kinase in a ligand-dependent manner.
Because most of T 3 is bound to carrier proteins such as thyroxine-binding globulin, albumin, and thyroid-binding prealbumin in vivo, only 0.3% of T 3 is unbound and free to interact with TR (29) . Although the concentrations of T 3 that lead to TRE-dependent responses normally occur in the picomolar range, we found that the minimum concentrations of T 3 , which activate Akt and eNOS, are somewhat higher, within the dissociation constant for TR (i.e., 0.1-1 nM) (22) . Indeed, in euthyroid human volunteers, injection of 100 g of T 3 increases free T 3 in the serum to levels Ͼ62 pM and is required to rapidly decrease BP and systemic vascular resistance (30) . These findings indicate that there are pharmacological effects of thyroid hormone on the cardiovascular system, which occur at concentrations well above what is required to initiate TRE-dependent responses. It remains to be determined, however, why higher concentrations of T 3 are required for Akt and eNOS activation compared with that of TRE-dependent responses.
An interesting, and perhaps clinically important, finding of this study is that eNOS may contribute to some of the rapid, vasodilatory effects of thyroid hormone (i.e., decrease in BP and increase in CBF). For example, T 3 has been shown to induce rapid relaxation of preconstricted resistance arterioles from isolated skeletal muscle (31) . Treatment with T 3 decreased BP in euthyroid WT mice, and to a greater extent, in hypothyroid WT mice. The decrease in BP by T 3 was greatly attenuated or absent in euthyroid and hypothyroid eNOS Ϫ/Ϫ mice, indicating the important contribution of eNOS in mediating the acute hemodyamic response to thyroid hormone. Interestingly, after MCAO, BP was substantially higher in eNOS Ϫ/Ϫ mice compared with that in WT mice (126 Ϯ 7 mmHg vs. 86 Ϯ 10 mmHg, P Ͻ 0.01), suggesting that the postvasodilatory response to ischemiareperfusion injury also appears to be mediated by eNOS. Taken together, these findings suggest that NO-mediated vasodilation is an important contributor to thyroid hormone's physiological effects on vascular tone and BP.
Although a reduction in systemic BP usually leads to greater severity in stroke, we found that T 3 paradoxically decreases cerebral infarct volume and improved NDS. This result, in part, is probably caused by the ability of T 3 to rapidly dilate cerebral blood vessels, leading to increases in CBF. Higher CBF has been shown to closely correlate with neuronal protection after focal cerebral ischemia (16) . We found that CBF was considerably higher in T 3 -treated WT mice compared with that in T 3 -treated eNOS Ϫ/Ϫ mice or vehicle-treated WT mice. Thus, it is likely that the increase in CBF and stroke protection by T 3 is predominantly mediated by eNOS, because these changes were relatively smaller or absent in eNOS Ϫ/Ϫ mice. However, in our study, we cannot exclude the possibility that T 3 could have additional neuroprotective effects via mechanisms beyond eNOS. For example, the activation of Akt in neuronal and inflammatory cells by T 3 may also contribute to the overall neuroprotective effects of thyroid hormone.
In summary, we have shown that T 3 rapidly activates eNOS via the TR͞PI3-kinase͞Akt pathway in vitro and in vivo. Treatment with T 3 increases the association of TR␣ 1 with PI3-kinase, leading to decreased stroke size and improved NDS after focal cerebral ischemia. These findings suggest an important non-TRE-dependent effect of thyroid hormone. Further clinical studies, however, are required to determine whether acute thyroid hormone, either alone or as adjunctive therapy, could be beneficial in patients with ischemic strokes.
Materials and Methods
Materials. T 3 , LY294002, and actinomycin D were purchased from EMD Biosciences (San Diego, CA). NH-3 was synthesized and dissolved in DMSO as described (32) . Anti-TR antibody (sc-739 and sc-737) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-p85␣ antibody was from Upstate Biotechnology (Lake Placid, NY). Unless specified, all other antibodies were obtained from Cell Signaling Technology (Danvers, MA).
Cell Culture. Human umbilical vein endothelial cells and bovine aortic endothelial cells were isolated and cultured as described (16, 18) . COS7, NIH 3T3, and HeLa cells were purchased from American Type Culture Collection (Manassas, VA). MEF were a gift from M. Kasuga (Kobe University, Kobe, Japan). Cells were stimulated under serum-starved conditions consisting of phenol-red-free Medium 199 (Gibco͞BRL, St. Louis, MO) or DMEM (Gibco͞BRL) with 0.4% charcoal-stripped FCS (HyClone, Logan, UT).
en's Hospital, and Massachusetts General Hospital. WT and eNOS Ϫ/Ϫ mice (both on C57BL͞6 backgrounds) were purchased from Jackson Laboratory (Bar Harbor, ME). Eight-week-old mice were made hypothyroid by daily i.p. injection of propylthiouracil (250 g) for 3 weeks (33 (25) (26) (27) . CBF was calculated according to the method of Van Uitert and Levy (36) and Betz and Iannotti (25) . CBF (ml͞100 g per min) ϭ [brain count (cpm) ϫ 0.3 (ml͞min)͞blood count (cpm) ϫ brain weight (g)] ϫ 100.
